EYENOVIA
Eyenovia is a biopharmaceutical company that provides portfolio of next generation topical eye treatments. It is a clinical stage, ophthalmic biopharmaceutical company that transforms the delivery of therapeutics for the treatment of prominent eye diseases, such as glaucoma, dry eyes, allergic eye disease and many others. Eyenovia’s breakthrough piezo-dispersion and microdosing technology enable a portfolio of first-in-class, next-generation, micro-therapeutics for the eye designed to reduce ocular and systemic toxicity and improve the risk-benefit profile of both new and existing therapeutics. Eyenovia was founded in 2014.
EYENOVIA
Industry:
Biotechnology Pharmaceutical
Founded:
2014-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.eyenovia.com
Total Employee:
11+
Status:
Active
Contact:
(917) 289-1117
Total Funding:
53.14 M USD
Technology used in webpage:
Amazon Amazon Route 53 Amazon Ohio Region
Current Advisors List
Board_member
2015-01-01
Board_member
2022-08-01
Board_member
2022-08-01
Advisor
2021-01-01
Current Employees Featured
Luke Clauson VP, R&D and Engineering @ Eyenovia
VP, R&D and Engineering
John Gandolfo Chief Financial Officer @ Eyenovia
Chief Financial Officer
Lee Kramm Consultant, Regulatory Affairs @ Eyenovia
Consultant, Regulatory Affairs
Kenneth Lee Lead Director @ Eyenovia
Lead Director
2022-01-01
Michael Rowe CEO @ Eyenovia
CEO
2022-08-01
Ginger Clasby VP, Clinical & Regulatory Affairs @ Eyenovia
VP, Clinical & Regulatory Affairs
2021-02-01
Founder
Stock Details
Investors List
Armistice Capital
Armistice Capital investment in Post-IPO Equity - Eyenovia
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Eyenovia
Key Employee Changes
Official Site Inspections
http://www.eyenovia.com Semrush global rank: 5.06 M Semrush visits lastest month: 1.63 K
- Host name: 45.184.227.35.bc.googleusercontent.com
- IP address: 35.227.184.45
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Eyenovia"
Eyenovia - Crunchbase Company Profile & Funding
Eyenovia’s breakthrough. piezo-dispersion and microdosing technology enable a portfolio of first-in-class, next-generation, micro-therapeutics for the eye …See details»
Eyenovia, Inc. - AnnualReports.com
Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics. …See details»
Eyenovia and Betaliq Explore Merger to Form New Ophthalmic
2 days ago Eyenovia, Inc. is an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic …See details»
Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse ...
2 days ago NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and …See details»
Eyenovia Provides Update on Restructuring Efforts | Eyenovia Inc.
Nov 22, 2024 Avenue Capital agrees to Company’s deferral of principal and interest payments on its outstanding debt until the end of February 2025. Eyenovia continues to evaluate a broad …See details»
Optejet Technology - Eyenovia
Traditional eye drops are approximately 40μL in volume and exceed the absorption capacity of the eye which is approximately 8μL. This can lead to medication overflow and possible overdosing that exposes patients to excess …See details»
News Releases - Eyenovia Inc.
Feb 5, 2025 Eyenovia plans to submit for U.S. device regulatory approval in Q4 of this year, marking a key step toward commercialization NEW YORK , Feb. 05, 2025 (GLOBE …See details»
EYENOVIA, INC.
(1) Estimated solely for the purpose of calculating the registration fee under Rule 457(o) of the Securities Act of 1933, as amended (the “Securities Act”).See details»
Eyenovia, Inc. Announces Debt Restructuring Including …
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing …See details»
Eyenovia Announces Updated Strategy and Corporate Priorities to …
Apr 8, 2024 Eyenovia, Inc. Company focusing on multi-billion dollar opportunity in pediatric progressive myopia represented by MicroPine, with interim analysis planned for 4Q 2024 and …See details»
Management - Eyenovia
Eyenovia’s management team is comprised of distinguished and proven members from a multitude of backgrounds. Michael Rowe. Chief Executive Officer and President. Bren Kern. …See details»
Arctic Vision (Shanghai) Biotechnology Co., Ltd.
Appointment of Mr. Rowe, Eyenovia’s current Chief Operating Officer, maintains continuity while bringing significant ophthalmic industry, operations and commercialization expertise to the …See details»
Eyenovia Plans All-Stock Reverse Merger With Betaliq
2 days ago By Colin Kellaher. Eyenovia on Thursday said it has signed a non-binding letter of intent to combine with clinical-stage pharmaceutical company Betaliq in an all-stock reverse …See details»
Eyenovia, Inc. Announces Debt Restructuring Including …
Feb 24, 2025 Amendment provides financial flexibility to the Company by deferring all interest as well as principal redemption payments through September 2025, while reducing near-term …See details»
Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse ...
Eyenovia, Inc. is an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform. …See details»
Eyenovia Enters Into Non-Binding Letter Of Intent To Effect …
2 days ago Eyenovia, Inc. is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet …See details»
VM - Eyenovia Enters Into Non-Binding Letter of Intent to Effect ...
1 day ago NEW YORK—Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, has announced that it has entered into a non-binding letter of intent contemplating a potential …See details»
Pipeline - Eyenovia
Eyenovia is evaluating other potential dry eye candidates for development in combination with the Optejet. Using the Optejet, dry eye sufferers will conveniently be able to dose themselves with …See details»
Eyenovia enters non-binding LOI to effect reverse merger with …
2 days ago Eyenovia , has entered into a non-binding letter of intent contemplating a potential reverse merger transaction with Betaliq, a clinical stage pharmaceutical company with a …See details»
Eyenovia Announces 1-for-80 Reverse Stock Split
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing …See details»